Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers

Liver International

Volumn 36, Issue 9, 2016, Pages 1304-1312

  Bang, Ulrich C ^a   Benfield, Thomas ^a,b   Hyldstrup, Lars ^a,b   Jensen, Jens Erik B ^a,b   Bendtsen, Flemming ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

beta blockers; cirrhosis; mortality; spontaneous bacterial peritonitis

Indexed keywords

PROPRANOLOL;

ADULT; ARTICLE; ASCITES; CONTROLLED STUDY; DANISH CITIZEN; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEPATORENAL SYNDROME; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; OBSERVATIONAL STUDY; PATIENT RISK; PERITONITIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; AGED; CAUSE OF DEATH; COMPLICATION; DENMARK; FACTUAL DATABASE; LIVER CIRRHOSIS; MORTALITY; MULTIVARIATE ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

AGED; CAUSE OF DEATH; DATABASES, FACTUAL; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONITIS; PROPRANOLOL; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84962642267     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13119     Document Type: Article

References (25)

1. de Francis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762–8.
2. Senzolo M, Cholongitas E, Burra P, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 1189–93.
3. Hillon P, Lebrec D, Munoz C, et al. Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528–31.
4. Pizcueta MP, de Lacy AM, Kravetz D, Bosch J, Rodes J. Propranolol decreases portal pressure without changing portocollateral resistance in cirrhotic rats. Hepatology 1989; 10: 953–7.
5. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439–47.
6. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: 105–10.
7. Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017–22.
8. Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012; 61: 967–9.
9. Leithead JA, Rajoriya N, Tehami N, et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015; 64: 1111–9.
10. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30–3.
11. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492–9.
12. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258–66.
13. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39: 38–41.
14. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011; 39: 26–9.
15. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006; 53: 441–9.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
17. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399–424.
18. Westreich D, Cole SR, Funk MJ, Brookhart MA, Sturmer T. The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf 2011; 20: 317–20.
19. Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta-blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol 2016; 64: 574–82.
20. Bossen L, Krag A, Vilstrup H, Watson H, Jepsen P. Non-selective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post hoc analysis of three RCTs with 1198 patients. Hepatology 2016; 63: 1968–76.
21. Mandorfer M, Bota S, Schwabl P, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 1680–90.
22. Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 43–8.
23. Madsen BS, Nielsen KF, Fialla AD, Krag A. Keep the sick from harm in spontaneous bacterial peritonitis: dose of beta-blockers matters. J Hepatol 2016; 64: 1455–6.
24. Fonager K, Sorensen HT, Rasmussen SN, Moller-Petersen J, Vyberg M. Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol 1996; 31: 154–9.
25. Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol 2013; 11: 217–23.